Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Multiple Myeloma
NCT07555938Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jun 2026
- Primary completion
- Oct 2028
- Countries
- 18
01
Overview
A Phase 3 trial of cevostamab in multiple myeloma (MM), sponsored by Roche. Started Jun 2026; status: recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07555938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555938.